Quality Assurance Program for Anti-Malarial Drug Testing
Author Information
Author(s): Lourens Chris, Watkins William M, Barnes Karen I, Sibley Carol H, Guerin Philippe J, White Nicholas J, Lindegardh Niklas
Primary Institution: Worldwide Antimalarial Resistance Network (WWARN), Oxford, UK
Hypothesis
The establishment of a quality assurance program will improve the reliability of anti-malarial drug testing across laboratories.
Conclusion
The proficiency testing program aims to enhance the quality of anti-malarial pharmacokinetic data by helping laboratories improve their drug analysis capabilities.
Supporting Evidence
- The QA/QC program aims to minimize bias from poor quality reference standards.
- The program is designed to help laboratories assess their drug analysis capabilities.
- By using a central source for standards, the cost of anti-malarial drug standards can be lowered.
Takeaway
This study created a program to help labs test malaria drugs better, making sure everyone uses the same high-quality standards.
Methodology
The program includes proficiency testing with spiked plasma samples and certified reference standards sent to participating laboratories.
Potential Biases
Bias may arise from variations in laboratory methods and the quality of reference materials used.
Limitations
The program's effectiveness depends on laboratory participation and adherence to quality standards.
Participant Demographics
The program is open to laboratories conducting clinical studies or research on anti-malarial drugs.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website